Existing law, the California Affordable Drug Manufacturing Act of 2020, requires the California Health and Human Services Agency to enter into partnerships resulting in the production or distribution of generic prescription drugs in order to, among other purposes, address shortages in the market and increase patient access to affordable drugs.
This bill would make a technical, nonsubstantive change to one of the provisions of that act.